179 12 years too late? Rethinking CFRD screening

• Published in: Journal of cystic fibrosis 2015-06, Vol.14, p.S104-S104
• Main Authors: McLean, M, Lambert, C, Gevers, E, Cowlard, J, Chaudry, R, Nwokoro, C
• Format: Article
• Language: English
• Subjects: Pulmonary/Respiratory
• ISSN: 1569-1993; 1873-5010
• DOI: 10.1016/S1569-1993(15)30356-8

Objectives UK practice for Cystic Fibrosis Related Diabetes (CFRD) screening varies widely. There is poor adherence to the current guidelines, which recommend annual screening of all patients >12 using oral glucose tolerance testing (OGTT). CFRD is associated with poor lung function and clinical status, and diagnosis is often made following clinical decline. Evidence linking CFRD to other morbidities supports a more proactive and sensitive screening process. We aimed to screen all CF patients >10 for CFRD using a Continuous Glucose Monitoring System (CGMS). Methods 114 CF patients were identified, of whom 52 were >10 y at the end of 2014. CGMS (Medtronic I-Pro™) was applied for 72 hours. Capillary blood glucose was independently recorded, along with a food diary. CFRD diagnosis was made in conjunction with a paediatric Diabetologist, according to International Society for Paediatric and Adolescent Diabetes (ISPAD) guidelines. Results 39/47 (83%) eligible (non-CFRD) patients were screened in 2014. Of those screened, 8 patients (21%) were diagnosed with CFRD (mean age 11.7±0.42 y), 4 (50%) of these were aged